Items where authors include "Harrington, KJ"
Article
Rudin, CM, Pandha, HS, Zibelman, M et al. (18 more authors) (2023) Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer, 11 (1). e005007. ISSN 2051-1426
Samson, A orcid.org/0000-0002-3081-7850, West, EJ orcid.org/0000-0001-7449-120X, Carmichael, J et al. (27 more authors) (2022) Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients. Cancer Immunology Research, 10 (6). pp. 745-756. ISSN 2326-6066
Appleton, E, Hassan, J, Chan Wah Hak, C et al. (7 more authors) (2021) Kickstarting Immunity in Cold Tumours: Localised Tumour Therapy Combinations With Immune Checkpoint Blockade. Frontiers in Immunology, 12. 754436. ISSN 1664-3224
Wilkins, AC, Fontana, E, Nyamundanda, G et al. (19 more authors) (2021) Differential and longitudinal immune gene patterns associated with reprogrammed microenvironment and viral mimicry in response to neoadjuvant radiotherapy in rectal cancer. Journal for ImmunoTherapy of Cancer, 9 (3). e001717. ISSN 2051-1426
Müller, LME, Holmes, M, Michael, JL et al. (20 more authors) (2019) Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21. Journal for ImmunoTherapy of Cancer, 7. 164. ISSN 2051-1426
Jennings, VA, Scott, GB orcid.org/0000-0003-0021-9400, Rose, AMS et al. (13 more authors) (2019) Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition. Molecular Therapy, 27 (6). pp. 1139-1152. ISSN 1525-0016
Huff, AL, Wongthida, P, Kottke, T et al. (12 more authors) (2018) APOBEC3 Mediates Resistance to Oncolytic Viral Therapy. Molecular Therapy - Oncolytics, 11. pp. 1-13.
Samson, A orcid.org/0000-0002-3081-7850, Scott, KJ orcid.org/0000-0002-5790-9579, Taggart, D et al. (36 more authors) (2018) Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. Science Translational Medicine, 10 (422). eaam7577. ISSN 1946-6234
Sharma, RA, Plummer, R, Stock, JK et al. (36 more authors) (2016) Clinical development of new drug-radiotherapy combinations. Nature Reviews Clinical Oncology, 13 (10). pp. 627-642. ISSN 1759-4774
Roulstone, V, Pedersen, M, Kyula, J et al. (14 more authors) (2015) BRAF- and MEK-targeted small molecule inhibitors exert enhanced antimelanoma effects in combination with oncolytic reovirus through ER stress. Molecular Therapy, 23 (5). pp. 931-942. ISSN 1525-0016
Roulstone, V, Khan, K, Pandha, HS et al. (8 more authors) (2015) Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors. Clinical Cancer Research, 21 (6). 1305 - 1312. ISSN 1078-0432
Seth, R, Khan, AA, Pencavel, TD et al. (8 more authors) (2015) Adenovirally Delivered Enzyme Prodrug Therapy with Herpes Simplex Virus-Thymidine Kinase in Composite Tissue Free Flaps Shows Therapeutic Efficacy in Rat Models of Glioma. Plastic and Reconstructive Surgery, 135 (2). 475 - 487. ISSN 0032-1052
Kyula, JN, Khan, AA, Mansfield, D et al. (16 more authors) (2013) Synergistic cytotoxicity of radiation and oncolytic Lister strain vaccinia in V600D/E BRAF mutant melanoma depends on JNK and TNF-α signaling. Oncogene, 33 (13). 1700 - 1712. ISSN 0950-9232
Twigger, K, Roulstone, V, Kyula, J et al. (14 more authors) (2012) Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway. BMC Cancer, 12. 368. ISSN 1471-2407
Simpson, GR, Horvath, A, Annels, NE et al. (10 more authors) (2012) Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer. British Journal of Cancer, 106. pp. 496-507. ISSN 0007-0920
Heinemann, L, Simpson, GR, Boxall, A et al. (8 more authors) (2011) Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer. BMC Cancer, 11 (1). ARTN 221. ISSN 1471-2407
Prestwich, RJD, Errington-Mais, F orcid.org/0000-0003-2155-534X, Harrington, KJ et al. (3 more authors) (2008) Oncolytic viruses: do they have a role in anti-cancer therapy? Clinical Medicine: Oncology, 2. pp. 83-96. ISSN 1177-9314
Conference or Workshop Item
Milhem, MM, Vanderwalde, AM, Bowles, TL et al. (16 more authors) (2022) Updated results from the skin cancer cohorts from an ongoing phase 1/2 multicohort study of RP1, an enhanced potency oncolytic HSV, combined with nivolumab (IGNYTE). In: 2022 ASCO Annual Meeting, 03-07 Jun 2022, Chicago, Illinois.